Although indolent B-cell lymphomas generally progress less rapdily and are associated with longer survival, better treatments are also needed for the many patients who relapse. ![]() 1Īxicabtagene ciloleucel has improved the outlook for patients with large B-cell lymphomas. In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |